Company Filing History:
Years Active: 2014-2025
Title: The Innovative Contributions of Silvina Garcia Rubio
Introduction
Silvina Garcia Rubio is a prominent inventor based in Princeton, NJ, known for her significant contributions to the field of medical science. With a total of 17 patents to her name, she has made remarkable advancements, particularly in the development of compounds that interact with the central nervous system.
Latest Patents
One of her latest patents is titled "Centrally-active ghrelin agonist and medical uses thereof." This innovative compound, 3-(1-(2,3-dichloro-4-methoxyphenyl)ethyl)-1-methyl-1-(1,3,3-trimethylpiperidin-4-yl)urea monohydrochloride salt, exhibits a high capability to permeate the blood-brain barrier. It demonstrates consistent ghrelin agonist activity at the central nervous system level. The compound is effective in treating and preventing medical conditions mediated by the ghrelin receptor in the central nervous system. Experimental tests have shown its high efficacy in treating neurotoxic damage, providing a useful combined pattern of neuroprotective effects at both central and peripheral levels. Additionally, it is beneficial for conditions requiring a reduction in heart rate and is pharmacologically active at low to moderate doses, indicating a favorable therapeutic index.
Career Highlights
Throughout her career, Silvina has worked with notable companies such as Helsinn Healthcare and Ono Pharmaceutical Co., Ltd. Her work has significantly impacted the pharmaceutical industry, particularly in developing innovative treatments for various medical conditions.
Collaborations
Silvina has collaborated with esteemed colleagues, including Claudio Giuliano and Claudio Pietra, contributing to her success and the advancement of her research.
Conclusion
Silvina Garcia Rubio's innovative work and dedication to medical science have led to significant advancements in the treatment of neurotoxic damage and other medical conditions. Her contributions continue to influence the field and inspire future innovations.